Orca-Q (inferred)

About Orca Bio

Orca Bio is a private, late-stage biotech pioneering high-precision cell therapies, with a lead program in Phase 3 for blood cancers. The company's technology platform aims to selectively deliver specific immune cell subsets to improve efficacy and reduce toxicity compared to traditional allogeneic stem cell transplants. With a seasoned leadership team and a focus on expanding into autoimmune diseases, Orca Bio is positioned to address significant unmet needs in transplantation medicine.

Therapeutic Areas